February 7, 2020 / 1:03 AM / 18 days ago

BRIEF-Immunicum AB Presents Updated Data From Phase Ii Mereca Trial Of Ilixadencel In Kidney Cancer

Feb 6 (Reuters) - Immunicum AB:

* REG-IMMUNICUM AB (PUBL) PRESENTS UPDATED DATA FROM PHASE II MERECA TRIAL OF ILIXADENCEL IN KIDNEY CANCER AT ASCO-SITC CLINICAL IMMUNO-ONCOLOGY SYMPOSIUM

* IMMUNICUM -SURVIVAL AS OF DEC WAS 54% IN ILIXADENCEL TREATMENT GROUP COMPARED WITH 37% OF PATIENTS IN CONTROL GROUP TREATED WITH SUNITINIB MONOTHERAPY

* IMMUNICUM - DATA AS OF DEC 2019 DEMONSTRATES SEPARATION IN KAPLAN-MEIER SURVIVAL CURVES IN FAVOR OF ILIXADENCEL TREATMENT GROUP Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below